Research programme: RNA-based therapeutics - ethris/Shire

Drug Profile

Research programme: RNA-based therapeutics - ethris/Shire

Latest Information Update: 29 Mar 2016

Price : $50

At a glance

  • Originator ethris; Shire
  • Class RNA
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bone disorders; Cystic fibrosis; Lung disorders

Most Recent Events

  • 22 Mar 2016 Preclinical trials in Lung disorders in Germany (IM) before March 2016
  • 22 Mar 2016 Preclinical trials in Bone disorders in Germany (Implant) before March 2016
  • 07 Jan 2013 Early research in Bone disorders in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top